# Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis

> **NCT05121402** · PHASE2 · WITHDRAWN · sponsor: **TLL Pharmaceutical, LLC**

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** TLL018
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05121402
- **Lead sponsor:** TLL Pharmaceutical, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-30
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decisions made by senior management of the company
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121402, "Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05121402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*